9 research outputs found
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Multiple myeloma and SARS-CoV-2 infection : clinical characteristics and prognostic factors of inpatient mortality
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple
myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73
hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were
compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted
at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were
male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was
moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required
by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive
ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients,
inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at
hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent
prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies
predictors of inpatient mortality among MM patients hospitalized with COVID-19
Managing the front‐line treatment for diffuse large B cell lymphoma and high‐grade B cell lymphoma during the COVID‐19 outbreak
The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome
Multiple myeloma and SARS-CoV-2 infection : clinical characteristics and prognostic factors of inpatient mortality
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19
Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple
myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73
hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were
compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted
at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were
male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was
moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required
by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive
ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients,
inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at
hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent
prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies
predictors of inpatient mortality among MM patients hospitalized with COVID-19
Effectiveness of standardized nursing care plans to achieve A1C, blood pressure, and LDL-C goals among people with poorly controlled type 2 diabetes mellitus at baseline: four-year follow-up study
Mortality after surgery in Europe: a 7 day cohort study
Background: Clinical outcomes after major surgery are poorly described at the national level. Evidence of heterogeneity between hospitals and health-care systems suggests potential to improve care for patients but this potential remains unconfirmed. The European Surgical Outcomes Study was an international study designed to assess outcomes after non-cardiac surgery in Europe.Methods: We did this 7 day cohort study between April 4 and April 11, 2011. We collected data describing consecutive patients aged 16 years and older undergoing inpatient non-cardiac surgery in 498 hospitals across 28 European nations. Patients were followed up for a maximum of 60 days. The primary endpoint was in-hospital mortality. Secondary outcome measures were duration of hospital stay and admission to critical care. We used χ² and Fisher’s exact tests to compare categorical variables and the t test or the Mann-Whitney U test to compare continuous variables. Significance was set at p<0·05. We constructed multilevel logistic regression models to adjust for the differences in mortality rates between countries.Findings: We included 46 539 patients, of whom 1855 (4%) died before hospital discharge. 3599 (8%) patients were admitted to critical care after surgery with a median length of stay of 1·2 days (IQR 0·9–3·6). 1358 (73%) patients who died were not admitted to critical care at any stage after surgery. Crude mortality rates varied widely between countries (from 1·2% [95% CI 0·0–3·0] for Iceland to 21·5% [16·9–26·2] for Latvia). After adjustment for confounding variables, important differences remained between countries when compared with the UK, the country with the largest dataset (OR range from 0·44 [95% CI 0·19 1·05; p=0·06] for Finland to 6·92 [2·37–20·27; p=0·0004] for Poland).Interpretation: The mortality rate for patients undergoing inpatient non-cardiac surgery was higher than anticipated. Variations in mortality between countries suggest the need for national and international strategies to improve care for this group of patients.Funding: European Society of Intensive Care Medicine, European Society of Anaesthesiology